Abivax stock jumped 38% after new obefazimod trial data eased the cancer-safety fears that had erased weeks of gains.
Abivax hisseleri 30 Haziran’da yeni Faz 3 güvenlik verileri sonrası yaklaşık %38 arttı. Hisse haziran başında kanser riski ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results